Reviva Pharmaceuticals Holdings, Inc. RVPH 深 滬
已收盤 05-08 16:00:00 美东时间
0.856
-0.006
-0.74%
華盛通- 最 高0.88
- 今 開0.87
- 成交量 33.09万股
- 最 低 0.83
- 昨 收 0.8624
- 總市值 1096.57万
- 52周最高 23.20
- 市盈率 靜 --
- 換手率 2.58%
- 52周最低 0.59
- 委 比 -79.43%
- 總股本 1281.04万
- 歷史最高 302.00
- 量 比 0.96
- 振 幅 5.80%
- 歷史最低 0.00
- 每 手 1
- 風險率 4.96%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA
Regulation FD Disclosure.On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") issued a letter to shareholders announcing certain business updates, including in connection with the
04-15 20:16
Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
04-08 21:20
Reviva Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Reviva Pharmaceuticals shares are trading lower after the company reported wors...
03-30 22:45
Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.10) by 455.88 percent. This is a 81.1 percent increase over losses of $(3.00) per
03-30 19:57
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals reported financial results for 2025 and recent business highlights, including FDA recommendations for a second Phase 3 trial for brilaroxazine in schizophrenia. The company highlighted favorable long-term safety and efficacy data from existing trials and plans to initiate the RECOVER-2 trial in mid-2026. They emphasized promising therapeutic potential, consistent safety, and broad-spectrum clinical activity. Additionally, R...
03-30 10:05
What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals shares are tumbling Thursday after pricing a $10 million public offering of over 6 million shares at $1.50 per share.
03-20 00:49
Reviva Pharmaceuticals Holdings shares are trading lower after the company announced a proposed public offering.
Reviva Pharmaceuticals Holdings shares are trading lower after the company anno...
03-19 04:17
Reviva Pharmaceuticals Commences Common Stock Offering; Terms Undisclosed
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system
03-19 04:11
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold
D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
03-06 05:39
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
